The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The evolution of treatment patterns and prognostic biomarkers in Latin American CLL patients
In this video, Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment and prognostic biomarker data from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL). The majority of the 400 chronic lymphocytic leukemia (CLL) patients studied were treated with chemotherapy and chemoimmunotherapy due to limited access to targeted agents. Although the usage of targeted Bruton’s tyrosine kinase (BTK) inhibitors has increased, Dr Castillo highlights the need to overcome the deficits in testing and access to targeted agents to improve outcomes for Latin American patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AstraZeneca: Research Funding; Roche: Consultancy; TG Therapeutics: Research Funding; Pharmacyclics: Consultancy, Research Funding; Cellectar: Consultancy; Beigene: Consultancy, Research Funding; Janssen: Consultancy; Abbvie: Consultancy, Research Funding.
